US Stock MarketDetailed Quotes

RAPP Rapport Therapeutics

Watchlist
  • 15.900
  • +0.130+0.82%
Close Feb 14 16:00 ET
581.57MMarket Cap-8.10P/E (TTM)

Rapport Therapeutics Key Stats

Earnings

Revenue Breakdown

Financial Indicators

Income Statement

Balance Sheet

Cash Flow

Rapport Therapeutics Earnings Estimates

Revenue

EPS

EBIT

Revenue is based on 3 analyst forecasts. Estimate data is from S&P, and actual data is from Income Statement

Currency: USD

Actual
Estimate
DatePeriodRevenue/EstimateEarnings Call
--2025/Q1-- / 0.000--
--2024/Q4-- / 0.000--
--2024/Q30.000 / 0.000--
--2024/Q20.000 / 0.000--
DatePeriodRevenue/EstimateEarnings Call
--2025/Q1-- / 0.000--
--2024/Q4-- / 0.000--
--2024/Q30.000 / 0.000--
--2024/Q20.000 / 0.000--
--------

Unlock Free Earnings Estimates

Rapport Therapeutics Earnings Reports

  • Rapport Therapeutics | 10-Q: Quarterly report

    Nov 7, 2024 07:33 ET

  • Rapport Therapeutics | 10-Q: Quarterly report

    Aug 8, 2024 07:44 ET

    • Trending Stocks

    Top Gaining Chinese Stocks Top Gaining Chinese Stocks
    No. Symbol % Chg
    HENDERA
    831152
    +30.00%
    Hengerda New Materials
    300946
    +20.01%
    Fujian Nebula Electronics.,Ltd
    300648
    +20.00%
    4
    Cubic Digital Technology
    300344
    +19.98%
    5
    HNAC Technology
    300490
    +19.95%
    Log In for the Full List
    Unlock Now
    Investment Course
    Top 5 Industries for Stock Trading under Trump's Second Term
    Stocks & Industries to Watch Under Trump's Second Presidency
    With mooomoo, find out which stocks and industries may benefit from Trump's second presidency, based on his first administration's track record.
    Discussing
    Trump 2.0 Era: How will global markets evolve?
    🎙️Discussion: 1. How will tariff policies affect the movement of key assets such as U.S. stocks, gold, and Bitcoin? 2. Given this context, Show More
    MicroStrategy Q4 2024 earnings conference call
    Reassessing Chinese Assets
    Following the introduction of China's groundbreaking DeepSeek technology, Wall Street giants have revised their investment outlooks for the Chinese market.